Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
100mg |
|
||
500mg |
|
||
Other Sizes |
|
ln Vivo |
In the periaqueductal gray (PAG), the injection of Thimerosal (THIM) results in a dose-dependent increase in the density of μ-opioid receptors (MORs). MOR density in the lateral periaqueductal gray (LPAG) and dorsomedial periaqueductal gray (DMPAG) areas is statistically significantly increased by treatment with increasing doses of Thimerosal. In the caudate putamen (CPU), Thimerosal likewise increases MOR density at a dosage of 3,000 μg Hg/kg. On the other hand, MOR density in the dentate gyrus (DG) is decreased when Thimerosal is administered at both higher doses [1]. Measuring 10 to 14 weeks after the injections, glutamate and aspartate levels rise but glycine and alanine levels fall due to the long-lasting effects of immerosal treatment (4 injections, im, 240 μg Hg/kg on postnatal days 7, 9, 11, and 15). Glutamate and aspartate concentrations at microdialysis time are unaffected by four injections of Thimerosal at a dose of 12.5 μg Hg/kg. When Thimerosal is applied to the perfusion fluid of the prefrontal cortex (PFC), glutamate overflow increases quickly. The Thimerosal impact on glutamate and aspartate is inhibited by coadministration of the neurosteroid dehydroepiandrosterone sulfate (DHEAS; 80 mg/kg; ip); the steroid does not affect these amino acids on its own. Thimerosal's acute effect on glutamate is likewise inhibited by co-application of dehydroepiandrosterone sulfate (DHEAS) in perfusion fluid[2].
|
---|---|
References |
[1]. Olczak M, et al. Neonatal administration of thimerosal causes persistent changes in mu opioid receptors in the ratbrain. Neurochem Res. 2010 Nov;35(11):1840-7.
[2]. Duszczyk-Budhathoki M, et al. Administration of thimerosal to infant rats increases overflow of glutamate and aspartate in the prefrontal cortex: protective role of dehydroepiandrosterone sulfate. Neurochem Res. 2012 Feb;37(2):436-47 |
Molecular Formula |
C11H15HGNAO2S
|
---|---|
Molecular Weight |
434.88
|
CAS # |
54-64-8
|
SMILES |
C1=CC=C(C(=C1)C(=O)[O-])[S-].[CH2]C.[Hg+].[Na+]
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : 100 mg/mL (229.95 mM )
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2995 mL | 11.4974 mL | 22.9948 mL | |
5 mM | 0.4599 mL | 2.2995 mL | 4.5990 mL | |
10 mM | 0.2299 mL | 1.1497 mL | 2.2995 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.